This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Diabetes Mellitus Type 2
and you are
between 35 and 60
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The hypoglycemic effect of Momordica Charantia has been evaluated in clinical trials in patients with type 2 diabetes mellitus. Important reductions in fasting plasma glucose, glycated hemoglobin (A1C), and fructosamine were observed. It is unknown whether this improvement is due to an improvement in insulin sensitivity and insulin secretion. The purpose of this study is to evaluate the effect of the administration of Momordica Charantia on insulin sensitivity and insulin secretion in patients with type 2 diabetes mellitus.

Provided treatments

  • Drug: Momordica charantia
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT02397447. The sponsor of the trial is University of Guadalajara and it is looking for 24 volunteers for the current phase.
Official trial title:
Effect of Momordica Charantia Administration on Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus, Without Pharmacological Treatment